Provided by Tiger Fintech (Singapore) Pte. Ltd.

Altimmune, Inc.

3.58
-0.0550-1.52%
Volume:1.74M
Turnover:6.27M
Market Cap:315.52M
PE:-3.05
High:3.68
Open:3.63
Low:3.55
Close:3.63
52wk High:11.16
52wk Low:2.90
Shares:88.26M
Float Shares:80.42M
Volume Ratio:0.92
T/O Rate:2.16%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.1725
EPS(LYR):-1.3388
ROE:-55.91%
ROA:-32.43%
PB:1.96
PE(LYR):-2.67

Loading ...

Altimmune Inc expected to post a loss of 32 cents a share - Earnings Preview

Reuters
·
Aug 04

60 Degrees Pharmaceuticals and Tulane University Sign Research Agreement to Study Tafenoquine Against Lyme and Bartonella Bacteria

GlobeNewswire
·
Jul 17

60 Degrees Pharmaceuticals to Submit MUMS (Minor Use/Minor Species) Designation Request to FDA for Tafenoquine for Acute Canine Babesiosis in 2025

GlobeNewswire
·
Jul 15

BUZZ-U.S. STOCKS ON THE MOVE-Tesla, AbbVie, McDonald's

Reuters
·
Jul 11

BUZZ-Altimmune falls after Goldman resumes coverage with "sell", citing competition

Reuters
·
Jul 10

Altimmune Price Target Maintained With a $12.00/Share by HC Wainwright & Co.

Dow Jones
·
Jun 27

BUZZ-Altimmune set for worst day ever after underwhelming data for liver disease drug

Reuters
·
Jun 26

Altimmune Down Over 56%, On Track for Largest Percent Decrease Since February 2017 -- Data Talk

Dow Jones
·
Jun 26

Stock Track | Altimmune Plummets 61.61% Despite Positive MASH Trial Results; Fibrosis Improvement Misses Mark

Stock Track
·
Jun 26

Altimmune Says Phase 2b Trial of Pemvidutide Shows 'Statistically Significant' MASH Resolution

MT Newswires Live
·
Jun 26

Altimmune's weight-loss drug meets main goal in fatty liver disease trial

Reuters
·
Jun 26

BRIEF-Altimmune Announces Positive Topline Results From The Impact Phase 2B Trial Of Pemvidutide

Reuters
·
Jun 26

Stock Track | Altimmune Plunges 6.49% Pre-market Despite Positive MASH Trial Results

Stock Track
·
Jun 26

Altimmune Shares Rise on Liver Disease Trial Data Presentation

Dow Jones
·
Jun 26

BRIEF-Altimmune Announces Initiation of RECLAIM Phase 2 Trial Evaluating the Efficacy and Safety of Pemvidutide in Alcohol Use Disorder

Reuters
·
May 19

Altimmune Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
May 13

Altimmune Secures Credit Facility of Up to $100 Million From Hercules Capital

MT Newswires Live
·
May 13

BRIEF-Altimmune Secures Up To $100 Mln In Credit Facility From Hercules Capital

Reuters
·
May 13

BRIEF-Altimmune Q1 Net Income USD -19.575 Million

Reuters
·
May 13

Altimmune Q1 EPS $(0.26) Beats $(0.36) Estimate, Sales $5.00K, Same YoY, Cash And Equivalents $150M

Benzinga
·
May 13